BridgeBio Oncology Therapeutics, Inc.
BBOT
$11.30
$0.232.08%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 432.17% | 6.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 63.43% | 30.06% | |||
| Operating Income | -63.43% | -30.06% | |||
| Income Before Tax | -57.40% | -28.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -57.40% | -28.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -57.40% | -28.93% | |||
| EBIT | -63.43% | -30.06% | |||
| EBITDA | -63.56% | -30.07% | |||
| EPS Basic | 97.96% | 7.13% | |||
| Normalized Basic EPS | 97.96% | 7.13% | |||
| EPS Diluted | 97.96% | 7.13% | |||
| Normalized Diluted EPS | 97.96% | 7.13% | |||
| Average Basic Shares Outstanding | 7,602.99% | 38.82% | |||
| Average Diluted Shares Outstanding | 7,602.99% | 38.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||